Cargando…

Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.

Detalles Bibliográficos
Autores principales:	Fiorentino, B., Di Stefano, P., Giuliani, C., Amatetti, C., Tinari, N., Natoli, C., Garufi, C., Iacobelli, S.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1992
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977987/ https://www.ncbi.nlm.nih.gov/pubmed/1419647

Ejemplares similares

Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease.
por: Natoli, C., et al.
Publicado: (1993)

Prognostic value of a novel circulating serum 90K antigen in breast cancer.
por: Iacobelli, S., et al.
Publicado: (1994)

Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2013)

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.
por: Jayson, G. C., et al.
Publicado: (1998)

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer
por: Belfiglio, Maurizio, et al.
Publicado: (2011)

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.
por: Pichert, G., et al.
Publicado: (1990)

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1996)

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
por: Pichert, G., et al.
Publicado: (1991)

Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha.
por: Reid, I., et al.
Publicado: (1991)

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study.
por: Facendola, G., et al.
Publicado: (1995)

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
por: Ravaud, A., et al.
Publicado: (1994)

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review
por: Sperduti, Isabella, et al.
Publicado: (2013)

Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity
Publicado: (1988)

Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.
por: von Rohr, A., et al.
Publicado: (1993)

Activity of interferon alpha, interleukin 6 and insulin in the regulation of differentiation in A549 alveolar carcinoma cells.
por: McCormick, C., et al.
Publicado: (1995)

Clinical Utility of Serum Interleukin-8 and Interferon-Alpha in Thyroid Diseases
por: Kobawala, Toral P., et al.
Publicado: (2011)

Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
por: Ligo, M., et al.
Publicado: (1989)

Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1995)

Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy
por: Sengupta, Sadhak, et al.
Publicado: (2014)

Identification of Interleukin1β as an Amplifier of Interferon alpha-induced Antiviral Responses
por: Robichon, Katharina, et al.
Publicado: (2020)

Breast Cancer “Tailored Follow-up” in Italian Oncology Units: A Web-Based Survey
por: Natoli, Clara, et al.
Publicado: (2014)

Influence of Interferon-Alpha Combined with Chemo (Radio) Therapy on Immunological Parameters in Pancreatic Adenocarcinoma
por: Karakhanova, Svetlana, et al.
Publicado: (2014)

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.
por: Goey, S. H., et al.
Publicado: (1996)

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
por: Becker, J C, et al.
Publicado: (2002)

Evaluation of interferon alpha 2b as adjunctive therapy for conjunctival melanoma
por: Benage, Matthew J., et al.
Publicado: (2019)

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
por: Henriksson, R., et al.
Publicado: (1998)

Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice
por: Ravaud, A, et al.
Publicado: (1999)

CD73-Dependent Regulation of Interferon AlphaA and Interleukin-10 in the Inflamed Mucosa
por: Sotnikov, Ilya, et al.
Publicado: (2010)

Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2
por: Giovannelli, Ilaria, et al.
Publicado: (2021)

Bilateral Retrobulbar Optic Neuropathy in the Setting of Interferon Alpha-2a Therapy
por: Fuzzard, Dujon R.W., et al.
Publicado: (2014)

Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
por: Wittling, Megen C., et al.
Publicado: (2021)

Low-Dose Interleukin-2 as an Alternative Therapy for Refractory Lupus Nephritis
por: Zhang, Xia, et al.
Publicado: (2021)

Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact
por: Alì, G, et al.
Publicado: (2009)

Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study
por: Cameron, D A, et al.
Publicado: (2001)

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms
por: Hasselbalch, Hans C., et al.
Publicado: (2021)

Therapy with high dose recombinant alpha 2 interferon (IFN-alpha 2) produces a depression in natural killer cell cytotoxicity.
por: Tank, B., et al.
Publicado: (1984)

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
por: Hoffmann, R., et al.
Publicado: (1998)

Similar biological effects of different low doses of interferon alpha in cancer patients.
por: Billard, C., et al.
Publicado: (1987)

Strain- and Sex-Dependent Circadian Changes in Abcc2 Transporter Expression: Implications for Irinotecan Chronotolerance in Mouse Ileum
por: Okyar, Alper, et al.
Publicado: (2011)

The P2X7 Receptor-Interleukin-1 Liaison
por: Giuliani, Anna Lisa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s278siltje8hsiac46qbdokfgk